BridgeBio (BBIO) CEO Neil Kumar Sells 10,000 Shares

What Happened

• Neil Kumar, CEO of BridgeBio Pharma (BBIO), reported the sale of 10,000 shares on September 17, 2026. The sales were two open-market disposals: 8,721 shares at $69.01 ($601,868) and 1,279 shares at $69.57 ($88,980), totaling approximately $690,848. These transactions are sales (disposals), not purchases.

Key Details

• Transaction dates/prices: Sep 17, 2026 — 8,721 shares @ $69.01; 1,279 shares @ $69.57.
• Total sold: 10,000 shares for roughly $690,848.
• Footnotes of note:
  • F1: Transactions effected pursuant to a Rule 10b5-1 sales plan adopted May 13, 2026.
  • F2/F4: Weighted-average sale price ranges reported ($68.52–$69.40 and $69.525–$69.64); detailed per-price breakdown available on request.
  • F3/F5: Reporting person disclaims beneficial ownership of certain shares except to extent of pecuniary interest; some shares are held in the "NK 2026 GRAT" trust (he is trustee/annuitant).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on Sep 21, 2026, which is within the typical 2-business-day Form 4 filing window for a Sep 17 transaction.

Context

• The sales were executed under a pre-established Rule 10b5-1 plan (adopted May 13, 2026). Such plans set predetermined trade instructions and can limit what the trade timing implies about the insider’s view of the company; this report does not disclose the reason for the sales.
• These are ordinary-share sales (code “S”); there were no option exercises, gifts, or awards reported in this filing.